News | April 27, 2023
Syngene International posts Q4 FY2023 consolidated profit at Rs. 178.7 Cr
The company has posted net profit of Rs.464.4 crores for the Financial Year ended March 31, 2023
The company has posted net profit of Rs.464.4 crores for the Financial Year ended March 31, 2023
FDA’s NME approvals declined substantially in 2022, causing overall New Drug Application (NDA) approvals to drop
The summit encompasses multiple verticals, spanning from pharmaceuticals, biotech, life sciences, and the Healthcare sector to ensure an unbiased and comprehensive view on the future of the function.
ProBioGen was able to carry on its rapid growth trajectory by completing a significantly increased number of projects.
Around 62% of the revenues came from the domestic market and 38% from the exports market for Q2 FY23 for a standalone business
Q1 net sales increased by 12.2% to € 5,198 million compared with the year-earlier quarter
The capex for FY22 stood at Rs 145 crore and is expected to be in the range of Rs 250-350 crore for the entire FY23 which would be funded through a mix of internal accruals and debt
R&D investment up 11.7% to 4.1 billion EUR in 2021 (20.0% of net sales)
Cipla has reported consolidated financial results for the period ended September 30, 2021
A mix of favorable government policies and a positive environment will create a win-win situation for all stakeholders
Subscribe To Our Newsletter & Stay Updated
